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Abstract Objective: To describe prevalence, prenatal diagnosis and epidemiology of congen-
ital hydronephrosis (CH) in Europe.
Material and method: Data from a large European database for surveillance of congenital mal-
formations (EUROCAT). The 20 participating registries are all based on multiple sources of
information and include information about livebirths, fetal deaths with gestational age 20
weeks and terminations of pregnancy after prenatal diagnosis of malformations. Included were
all cases with CH and born 1995e2004.
Results: There were 3648 cases with CH giving an overall prevalence of 11.5 cases per 10,000
births. The large majority of cases were livebirths (3506, 96% of total) and only 17 cases were
fetal deaths and 120 were terminations of pregnancy. Almost all livebirths were alive 1 week
after birth. Boys accounted for 72% of all cases. A high proportion of the cases (86%) had an
isolated renal malformation. There were large regional differences in prevalence of CH ranging
from 2 to 29 per 10,000 births. There was little regional variation in the prevalence of postna-
tally diagnosed cases while there were large regional differences in prevalence of prenatally
diagnosed cases.
Conclusion: Cases with CH are mainly livebirths, boys and survive the first week after birth.
The large difference in prevalence seems to be related to the availability of prenatal screening
in the region. The impact of over-diagnosis and potential over-treatment in regions with high
prevalence or under-diagnosis with implications for renal function later in life in regions with
low prevalence needs further investigation.
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Introduction
The natural history of congenital hydronephrosis (CH) has
changed dramatically over the last decades. Up to the
1980s, CH was mainly diagnosed in infants admitted to
hospital with urosepsis or UTIs. The main diagnostic test for
CH was intravenous urography. Later ultrasound became
the first diagnostic test for investigation of renal malfor-
mations in infants. During the last 25 years an increasing
number of fetuses have been diagnosed prenatally with CH
using ultrasound investigation, either on indication or as
a screening method [1].
Many European countries have now developed
national or regional programmes for both prenatal and
postnatal follow up and treatment for fetuses and
infants with CH. In earlier time periods most infants
diagnosed with CH were referred for surgery in infancy.
Today the majority of infants are followed up with
ultrasound and/or renal functioning tests every 3
months and surgery is only recommended for a small
proportion of infants and children. The main indication
for surgery is decreasing function of the affected
kidney [2].
A prenatal diagnosis of CH may increase anxiety for the
expectant parents and they may ask questions that need to
be answered: Is the risk of fetal or neonatal death
increased? How much will the diagnosed malformation
impact on the quality of life in infancy and childhood? A
prenatal diagnosis of CH also raises the questions of
whether any interventions during pregnancy will be needed
and allows postnatal investigations and treatment to be
planned.
The aim of this study is to present data on prevalence,
prenatal diagnosis and epidemiology of CH in Europe using
a large European database of congenital malformations
(EUROCAT).
Methods
The study is based on routinely collected data from 20
European registries of congenitalmalformations (EUROCAT).
The EUROCAT registries are population based, and the
geographically defined populations and methods of case
ascertainment of EUROCAT have been described elsewhere
[3]. For further details on population coverage and
registration methods see www.eurocat.ulster.ac.uk/memb
erreg/. The registries are all based on multiple sources of
information including hospital records, birth and death
certificates, and post-mortem examinations, and include
information about livebirths, fetal deaths with gestational
age (GA) 20 weeks and terminations of pregnancy
(TOP) after prenatal diagnosis of malformations. All struc-
tural malformations, syndromes and chromosomal anoma-
lies are included in the database except minor and poorly
specified malformations found on a list of exclusion http://
www.eurocat.ulster.ac.uk/pdf/EUROCAT-Guide-1.3.pdf.
Only cases with the diagnosis confirmed postnatally are
included in the database.
All cases with an ICD9 or ICD10 code with CH (75320 and
Q620) and born in the period 1995e2004 were included in
this study. Cases with an additional chromosomal anomaly
were excluded (173 cases). Further cases coded with both
CH and PUV or prune belly syndrome were excluded.
The EUROCAT definition of CH was ‘‘obstruction of the
urinary flow from kidney to bladder’’ and from 2003 it was
added ‘‘only if renal pelvis is 10 mm or more after birth’’.
According to the definition CH caused by VUR is not
included in the EUROCAT database and is mentioned on the
exclusion list.
The data included in the analysis are: birth outcome,
year of birth, sex, birth weight, gestational age, time of
diagnosis (prenatally or postnatally), death within first
week after birth and associated malformations.
The EUROCAT flowchart for multiple malformations was
used tofind thepotentialmultiplemalformationcaseshttp://
www.eurocat.ulster.ac.uk/pdf/EUROCAT-Guide-1.3.pdf.
These cases were manually reviewed by two geneticists (DW
and IB) and classified as isolated renalmalformation,multiple
malformations (two ormoremajormalformations in different
organ systems), syndrome or association.
A questionnaire was send to all local registries regarding
the postnatal follow up and treatment of infants with CH.
Information on prenatal screening programmes in
Europe based on the situation in the year 2004 was
extracted from an earlier EUROCAT publication [4]. At that
time one or more prenatal ultrasound investigations was
offered to all pregnant women in all countries except Ire-
land, Malta and Netherlands. All countries offering ultra-
sound screening had one scan performed in the second
trimester of pregnancy.
Total number of births covered by the 20 registries in the
years included in the study was 3,160,728.
Results
During the 10-year study period there were 3648 cases with
CH reported to EUROCAT from the 20 local registries. This
gives an overall prevalence of CH of 11.5 per 10,000 births
with a large regional difference within Europe in preva-
lence of CH (Table 1 and Fig. 1).
The large majority of the cases were livebirths, 3506
(96%), and there were only 17 fetal deaths with GA 20
weeks and 120 TOP after prenatal diagnosis (birth
outcome was unknown for 5 cases). Median GA for fetal
deaths was 31 weeks (range 23e40 weeks), and median GA
for TOP was 21 weeks with 90 before 24 weeks and 22 at
24 weeks or later (GA at termination was unknown for 8
cases).
Among livebirths there were 2523 boys (72%) and 977
girls (28%). In six livebirth cases the gender of the case was
not recorded in the registry.
Time of diagnosis was prenatal in 2664 cases (73% of
total cases). There were large regional differences in the
proportion of prenatally diagnosed cases, ranging from less
than 30% in Campania and SE Ireland to more than 80% in
Basque Country (81%), Vaud (82%), Wales (82%), Strasbourg
(84%), Paris (88%) and Barcelona (95%) (Table 1 and Fig. 1).
Fig. 1 shows the relationship between overall prevalence of
CH and the prevalence of CH diagnosed prenatally.
For postnatally diagnosed cases 675 of 902 cases (75%)
were diagnosed within the first week and only 17 cases were
reported after 1 year of age. However, only four registries
included cases diagnosed after the first year of life.
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The cases were classified into three groups: 3135 (86%)
cases had an isolated renal malformation, 416 (11%) were
multiple malformed, and 97 (3%) were diagnosed with
a recognized syndrome or association. Among the multiple
malformed cases there were 47 cases with hypospadia (11%
of all multiple malformed) and 57 cases with a ventricular
septal defect (14% of all multiple malformed cases).
Among livebirths 3078/3506 (88%) had an isolated renal
malformation compared to 46/120 (38%) of TOP (P< 0.001)
(Table 2).
Comparing registries there was a clear relationship
between the total prevalence of CH and the prevalence of
CH as an isolated renal malformation (Fig. 2).
GA at prenatal diagnosis was available for 1733 liveborn
infants with an isolated renal malformation. The most
frequent GAs at diagnosis were 19e22 weeks and 32e34
weeks (Fig. 3). These are the usual ages at which ultrasound
screening is offered in the second and third trimesters [4].
Fifteen registries had information on survival until 1
week after birth. Only 17 of 2051 cases (0.8%) were
Table 1 Time period, total birth, prevalence and age at diagnosis of CH by registry
Registry Country Years
included
Total
births
Total
cases
Total
prevalencea
Cases with
prenatal
diagnosis
Prevalence
prenatal
diagnosisa
% Prenatal
diagnosis
Age at
postnatal
diagnosis
Wielkopolska Poland 1999e2004 206,481 44 2.1 22 1.1 50 <1 year
N Netherlands Netherlands 1995e2004 198,521 71 3.6 45 2.3 63 <1 year
SE Ireland Ireland 1997e2003 41,625 17 3.6 4 1.0 24 <1 year
Cork and Kerry Ireland 1996e2003 63,007 24 3.8 13 2.1 54 <1 year
Campania Italy 1996e2004 479,458 245 5.1 52 1.1 21 <1 month
Zagreb Croatia 1995e2004 59,253 33 5.6 22 3.7 67 <1 year
Malta Malta 1995e2004 43,128 24 5.6 17 3.9 71 <1 week
S Portugal Portugal 1995e1998,
2000e2004
155,882 98 6.3 69 4.4 70 <1 month
Basque Spain 1995e2004 173,245 116 6.7 94 5.4 81 <1 year
Tuscany Italy 1995e2004 261,867 205 7.8 125 4.8 61 <1 year
Odense Denmark 1995e2004 55,677 44 7.9 29 5.2 66 >1 year
Vaud Switzerland 1995e2004 73,544 77 10.5 63 8.6 82 >1 year
Barcelona Spain 1995e2003 113,133 131 11.6 125 11.0 95 <1 week
IMER Italy 1995e2004 269,875 325 12.0 210 7.8 65 <1 year
Strasbourg France 1995e2001 94,802 122 12.9 103 10.9 84 >1 year
Mainz Germany 1995e2004 33,419 63 18.9 29 8.7 46 <1 week
Paris France 1995e2004 382,584 814 21.3 777 20.3 95 <1 week
Styria Austria 1995e2004 110,529 238 21.5 135 12.2 57 <1 year
Hainaut Belgium 1995e2004 122,389 312 25.5 198 16.2 63 <1 year
Wales UK 1998e2004 222,309 645 29.0 532 23.9 82 >1 year
Total 3,160,728 3648 11.5 2664 8.4 73
a Rate per 10,000 births.
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Figure 1 Total prevalence and prevalence of prenatally diagnosed cases with CH by registry, sorted by total prevalence.
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reported with a date of death within the first week and
1979 cases were alive at 1 week of age. Survival was
unknown for 55 cases (2.7%) from these 15 registries.
Discussion
This study found an overall prevalence of CH in European
regions of 11.5 per 10,000 births with a large regional
difference. Very few studies have been published on the
prevalence of CH for comparison with our study. Studies on
prenatally detected CH show a rate as high as 1%, but these
studies also included less severe cases that resolved spon-
taneously after birth [5,6]. We are aware of three studies
published from 1989 to 1993. A British study [7] found 13
cases in 6292 pregnant women reaching 28 weeks of
gestation, the age at which the ultrasound was performed.
One case was diagnosed postnatally and 12 cases prena-
tally. The prevalence of CH in this study was 20.7 per
10,000 births. In Finland they found 14 cases in 4586 fetuses
(one diagnosed postnatally) giving a prevalence of 30.5 per
10,000 births [8].
A large population-based British study based on notifi-
cations to a registry found 113 cases in 242,628 births giving
a prevalence of 4.7 per 10,000 births [9]. In this study 97
cases were diagnosed prenatally (86% of total cases).
There are several limitations to our study. First of all we
did not have a clear definition of the severity of CH before
2003. At that time it was decided to include only those
cases with a renal pelvis of at least 10 mm after birth.
There may be less severe cases included before 2003 or the
size of the renal pelvis may be unknown to the registry.
Total prevalence for CH was 9.1 per 10,000 births for the
years 2003e2004 compared to 11.5 per 10,000 births for the
whole study period. This decrease is not wholly explained
by a change in definition as some registries include late
diagnosed cases, which means that cases born in 2004 may
not have been reported to the central database at the time
of data extraction for the study.
Although we do not include CH based on VUR, there may
be cases notified to the local registries where the etiology
of the CH was not yet known. We know that this has
occurred in Wales, Styria and Mainz and may explain part of
their high prevalence.
Some registries only include cases diagnosed within the
first week of life and have difficulties in the follow up of
cases after the first discharge from hospital. Table 1 shows
the maximum age at diagnosis by registry for cases included
in the study. Four registries only include cases diagnosed up
to 1 week after birth and three of these have a low post-
natal prevalence of CH (Barcelona, Malta and Paris) (Fig. 1).
Furthermore, we are not able to discriminate between
unilateral and bilateral CH. The data are extracted based
on the ICD code, and there is only one code for CH in both
ICD9 and ICD10. This means that we do not know if all TOP
were cases with bilateral CH.
The strength of our study is the large dataset collected
over many years. The database is without bias in collecting
data specific for CH, and we have good data on both
prenatal diagnosis and postnatal confirmation of the
diagnosis.
Despite the limitations, we can conclude that there are
very large regional differences in the prevalence of CH in
Europe. The large difference in prevalence in this study
seems to be explained by differences in prenatal diagnosis.
The three countries with no prenatal ultrasound screening
Table 2 Relation between birth outcome and associated
malformations for cases with CH
TOP Fetal death Livebirth
Isolated renal 46 (38%) 8 (47%) 3078 (88%)
Multiple malformations 59 (49%) 7 (41%) 349 (10%)
Syndrome or association 15 (13%) 2 (12%) 79 (2%)
Total 120 17 3506
Prevalence of isolated and non-isolated congenital hydronephrosis
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Figure 2 Prevalence of isolated and non-isolated cases with CH, by registry.
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offered during the whole study period all had a low prev-
alence at 3.6e5.6 per 10,000 births (Ireland, Malta and
Netherlands). Many countries with a second trimester
screening offered also offered a third trimester scan,
although mainly for biometric purposes. Among these
countries (Austria, Belgium, France, Germany, Italy, Por-
tugal and Spain) [4] most had a high prevalence of CH. The
number of postnatally diagnosed cases and the number of
cases with associated anomalies seem to be more uniform
than the prevalence of prenatally diagnosed and isolated
cases with CH (Figs. 1 and 2).
However, the definition of CH needs to be standardized.
Comparison of regional prevalence is difficult due to
between-country variations in the use of prenatal ultra-
sound investigations, different interpretations of the defi-
nition of CH and the availability of follow-up data for each
case. These factors contribute to the overall regional
prevalence of CH.
The typical case with CH is a liveborn boy who is alive 1
week after birth. We found a highly significant difference in
the rate of associated anomalies between livebirths and
TOP. TOP were performed in only 46 out of 3135 cases with
isolated renal malformation. In the European regions
included in this study the diagnosis of fetal hydronephrosis
is only on rare occasions followed by TOP. In some countries
such as Poland TOP are only allowed for severe, usually
lethal anomalies and not allowed for CH.
Many areas have a regional follow-up programme for
infants diagnosed with CH and we are aware of follow-up
programmes in Wales, Spain and Denmark [10]. These
includes regular ultrasound investigations, renal function
tests and in some places also prophylactic antibiotics. From
the questionnaire to the local registries we also know that
prophylactic antibiotics are given in Wales, Basque Country
and Croatia.
Surgery is performed if renal function is/becomes
impaired, although there may also be other indications such
as size, pain or recurrent infections. The actual clinical
controversy is that there is currently no way of differenti-
ating between ‘‘harmful’’ and ‘‘harmless’’ obstruction [1].
The management approach must balance the costs and risks
of universal surgery with the costs of close monitoring and
the risk of renal deterioration during the period of
‘‘watchful waiting’’.
Our study raises the question of whether it is reasonable
to believe that there is this large regional difference in the
prevalence of CH in Europe. If not, is there over-treatment/
control in regions with a high prevalence or is the outcome
later in life worse in those regions with low prenatal
detection of CH and therefore an apparently low preva-
lence of CH in infancy? The question will be very difficult to
answer, but efforts should be done to find the optimal
follow-up programme and level of treatment.
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